[go: up one dir, main page]

RU2001122164A - CRYSTAL CALCIUM SALT BIS [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] - pyrimidine-5-yl] - (3R, 5S) -3.5 -DIGIDROXYHEPT-6-NEW ACID] - Google Patents

CRYSTAL CALCIUM SALT BIS [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] - pyrimidine-5-yl] - (3R, 5S) -3.5 -DIGIDROXYHEPT-6-NEW ACID]

Info

Publication number
RU2001122164A
RU2001122164A RU2001122164/04A RU2001122164A RU2001122164A RU 2001122164 A RU2001122164 A RU 2001122164A RU 2001122164/04 A RU2001122164/04 A RU 2001122164/04A RU 2001122164 A RU2001122164 A RU 2001122164A RU 2001122164 A RU2001122164 A RU 2001122164A
Authority
RU
Russia
Prior art keywords
crystalline form
form according
methyl
methylsulfonyl
fluorophenyl
Prior art date
Application number
RU2001122164/04A
Other languages
Russian (ru)
Other versions
RU2236404C2 (en
Inventor
Найджел Филлип ТЕЙЛОР
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900339.4A external-priority patent/GB9900339D0/en
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2001122164A publication Critical patent/RU2001122164A/en
Application granted granted Critical
Publication of RU2236404C2 publication Critical patent/RU2236404C2/en

Links

Claims (8)

1. Кристаллическая форма кальциевой соли бис[(Е)-7-[4-(4-фторфенил)-6-изопропил-2-[метил(метилсульфонил)амино]-пиримидин-5-ил](3R, 5S)-3, 5-дигидроксигепт-6-еновой кислоты] формулы I1. The crystalline form of the calcium salt of bis [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3 , 5-dihydroxyhept-6-enoic acid] of the formula I
Figure 00000001
Figure 00000001
 или ее гидрат, имеющая порошковую рентгенограмму с характерными пиками при значениях угла 2-тета (2θ)=4,92; 11,50; 6,93; 9,35; 23,12 и 18,76°.or its hydrate having a powder x-ray with characteristic peaks at 2-theta angle (2θ) = 4.92; 11.50; 6.93; 9.35; 23.12 and 18.76 °. 2. Кристаллическая форма по п.1, которая является кристаллической гидратированной формой.2. The crystalline form according to claim 1, which is a crystalline hydrated form. 3. Фармацевтическая композиция, содержащая кристаллическую форму по п.1 или 2 вместе с фармацевтически приемлемым носителем.3. A pharmaceutical composition comprising a crystalline form according to claim 1 or 2 together with a pharmaceutically acceptable carrier. 4. Способ получения кристаллической формы для гидратированной формы по п.1, который включает формирование кристаллов из смеси соединения формулы 1, воды и одного или более органических растворителей.4. A method for producing a crystalline form for a hydrated form according to claim 1, which comprises forming crystals from a mixture of a compound of formula 1, water and one or more organic solvents. 5. Способ по п.4, в котором органический растворитель выбран из ацетонитрила, ацетона или смеси метанола и метил- третбутилового эфира.5. The method according to claim 4, in which the organic solvent is selected from acetonitrile, acetone, or a mixture of methanol and methyl tert-butyl ether. 6. Способ получения фармацевтической композиции по п.3, который включает смешивание кристаллической формы по п.1 с фармацевтически приемлемым носителем.6. The method of obtaining the pharmaceutical composition according to claim 3, which includes mixing the crystalline form according to claim 1 with a pharmaceutically acceptable carrier. 7. Применение кристаллической формы по п.1 для изготовления лекарственного препарата.7. The use of the crystalline form according to claim 1 for the manufacture of a medicinal product. 8. Способ лечения болезненного состояния, для которого полезно ингибирование ГМГ-СоА-редуктазы, который включает введение теплокровным млекопитающим эффективного количества кристаллической формы по п.1.8. A method of treating a disease state for which the inhibition of HMG-CoA reductase is useful, which comprises administering to the warm-blooded mammal an effective amount of the crystalline form according to claim 1.
RU2001122164/04A 1999-01-09 1999-12-23 Crystalline hydrated form of bis-[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidine-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt, method for its preparing, pharmaceutical composition, method for its preparing and method for treatment RU2236404C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9900339.4 1999-01-09
GBGB9900339.4A GB9900339D0 (en) 1999-01-09 1999-01-09 Chemical compounds

Publications (2)

Publication Number Publication Date
RU2001122164A true RU2001122164A (en) 2003-05-20
RU2236404C2 RU2236404C2 (en) 2004-09-20

Family

ID=10845719

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001122164/04A RU2236404C2 (en) 1999-01-09 1999-12-23 Crystalline hydrated form of bis-[(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidine-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid] calcium salt, method for its preparing, pharmaceutical composition, method for its preparing and method for treatment

Country Status (32)

Country Link
US (2) US6589959B1 (en)
EP (1) EP1144389B1 (en)
JP (2) JP4996786B2 (en)
KR (1) KR100645858B1 (en)
CN (1) CN1213033C (en)
AT (1) ATE282027T1 (en)
AU (1) AU762909B2 (en)
BR (1) BR9916786A (en)
CA (1) CA2356212C (en)
CZ (1) CZ299843B6 (en)
DE (1) DE69921855T2 (en)
DK (1) DK1144389T3 (en)
EE (1) EE05033B1 (en)
ES (1) ES2232194T3 (en)
GB (1) GB9900339D0 (en)
HK (1) HK1040989B (en)
HU (1) HU228116B1 (en)
ID (1) ID29432A (en)
IL (1) IL143977A0 (en)
IN (2) IN213326B (en)
IS (1) IS2410B (en)
MX (1) MX223771B (en)
NO (1) NO320189B1 (en)
NZ (1) NZ512560A (en)
PL (1) PL201800B1 (en)
PT (1) PT1144389E (en)
RU (1) RU2236404C2 (en)
SI (1) SI1144389T1 (en)
SK (1) SK285807B6 (en)
TR (1) TR200101894T2 (en)
WO (1) WO2000042024A1 (en)
ZA (1) ZA200105187B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10135493A1 (en) * 2001-07-20 2003-01-30 Jobst Krauskopf New use of calcium compounds, e.g. calcium L-lactate, for treating hypercholesterolemia and associated diseases such as coronary heart disease
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
JP4616168B2 (en) * 2003-04-25 2011-01-19 日本ケミファ株式会社 (2S, 3S) -3-[[(1S) -1-isobutoxymethyl-3-methylbutyl] carbamoyl] oxirane-2-carboxylic acid salt
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (en) * 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2005051921A1 (en) * 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CZ200486A3 (en) * 2004-01-16 2005-08-17 Zentiva, A.S. Process for preparing hemicalcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
EP1709008A1 (en) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salts of hmg-coa reductase inhibitors and use thereof
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US7241800B2 (en) 2004-03-17 2007-07-10 Mai De Ltd. Anhydrous amorphous form of fluvastatin sodium
US20080234302A1 (en) * 2004-09-27 2008-09-25 Mohammad Rafeeq Novel Processes for Preparing Amorphous Rosuvastatin Calcium and a Novel Polymorphic Form of Rosuvastatin Sodium
US7932387B2 (en) * 2005-01-31 2011-04-26 Basf Se Crystalline forms of rosuvastatin calcium salt
US9150518B2 (en) 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
CZ299215B6 (en) * 2005-06-29 2008-05-21 Zentiva, A. S. Process for preparing hemi-calcium salt of rosuvastatin, i.e. (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
EP1805148A2 (en) * 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
HU227696B1 (en) * 2006-04-13 2011-12-28 Egyt Gyogyszervegyeszeti Gyar Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it
WO2008015563A2 (en) * 2006-08-04 2008-02-07 Glenmark Pharmaceuticals Limited Salts of rosuvastatin and processes for their preparation
WO2008036286A1 (en) * 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
US20080249141A1 (en) * 2007-04-06 2008-10-09 Palepu Nageswara R Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
EP2336116A1 (en) * 2009-12-16 2011-06-22 LEK Pharmaceuticals d.d. Process for the preparation of key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof
WO2011074016A1 (en) 2009-12-17 2011-06-23 Matrix Laboratories Ltd Novel polymorphic forms of rosuvastatin calcium and process for preparation of the same
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012069394A1 (en) 2010-11-22 2012-05-31 Basf Se Multicomponent system of rosuvastatin calcium salt and sorbitol
DE202012011888U1 (en) 2011-04-18 2013-03-21 Basf Se Crystalline multicomponent system of rosuvastatin calcium salt and vanillin
WO2014050874A1 (en) * 2012-09-27 2014-04-03 東和薬品株式会社 Novel crystalline form of rosuvastatin calcium and production method therefor
RO129060B1 (en) 2013-04-25 2014-11-28 Antibiotice S.A. Stable pharmaceutical composition with amorphous rosuvastatin calcium
CN103755643A (en) * 2013-12-31 2014-04-30 连云港金康医药科技有限公司 Rosuvastatin calcium I crystal form
CN105153040B (en) * 2015-10-15 2018-04-13 江苏师范大学 Rosuvastain calcium novel crystal forms and preparation method thereof
PL3445751T3 (en) 2016-04-18 2023-09-18 Morepen Laboratories Limited New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium
CN105837516B (en) * 2016-05-16 2018-07-10 山东新时代药业有限公司 A kind of rosuvastain calcium crystal form and preparation method thereof
CN114105885A (en) * 2020-08-28 2022-03-01 广东东阳光药业有限公司 Preparation method of rosuvastatin calcium crystal form A
TW202302090A (en) * 2021-04-30 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 Dosage regimen for thrombopoietin receptor agonist

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
JP2648897B2 (en) * 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
GB9900339D0 (en) * 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds

Similar Documents

Publication Publication Date Title
RU2001122164A (en) CRYSTAL CALCIUM SALT BIS [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] - pyrimidine-5-yl] - (3R, 5S) -3.5 -DIGIDROXYHEPT-6-NEW ACID]
JP4996786B2 (en) The crystalline compound bis [(E) -7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S) -3, 5-Dihydroxy-6-heptenoic acid] calcium salt
RU2002124621A (en) CRYSTAL SALTS 7- [4- (4-fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidine-5-yl - (3R, 5S) -3, 5-dihydroxy-enept-6
CA2537962A1 (en) Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt
RU2403251C2 (en) 2,4-di(hetero)arylaminopyrimidine derivatives as zap-70 inhibitors
CA2527314A1 (en) Improved production of rosuvastatin calcium salt
RU98114081A (en) ARILETHENSULPHANAMIDE DERIVATIVES AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS
CA2429979A1 (en) Treatment of statin side effects
RU2007126746A (en) NEW HYDANTOIN DERIVATIVES AS METALLOPROTEINASIS INHIBITORS
WO2005021511A1 (en) A novel process for amorphous rosuvastatin calcium
EP3445751B9 (en) New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium